Austin McCullough, Charles D. Chen, Brian A. Gordon, Nelly Joseph-Mathurin, Clifford R. Jack Jr, Robert Koeppe, Russ Hornbeck, Deborah Koudelis, Nicole S. McKay, Diana A. Hobbs, Shaney Flores, Sarah J. Keefe, Neelum T. Aggarwal, Ricardo F. Allegri, Sarah B. Berman, Thomas Bird, Sandra E. Black, William S. Brooks, Jasmeer P. Chhatwal, Gregory S. Day, Martin R. Farlow, Nick C. Fox, Serge Gauthier, Lawrence S. Honig, Ging-Yuek Hsiung, Mathias Jucker, Johannes Levin, Mario Masellis, Colin Masters, Patricio Chrem Mendez, John M. Ringman, B. Joy Snider, Stephen Salloway, Peter R. Schofield, Hiroyuki Shimada, Kazushi Suzuki, Christopher H. van Dyck, Gregory Klein, David B. Clifford, Carlos Cruchaga, Jason Hassenstab, Yan Li, Eric McDade, Susan Mills, John C. Morris, Richard J. Perrin, Charlene Supnet-Bell, Guoqiao Wang, Chengjie Xiong, Randall J. Bateman, Tammie L. S. Benzinger, for the DIAN-TU Study Team
{"title":"在DIAN-TU-001试验中，更纳单抗对神经成像生物标志物的局部影响","authors":"Austin McCullough, Charles D. Chen, Brian A. Gordon, Nelly Joseph-Mathurin, Clifford R. Jack Jr, Robert Koeppe, Russ Hornbeck, Deborah Koudelis, Nicole S. McKay, Diana A. Hobbs, Shaney Flores, Sarah J. Keefe, Neelum T. Aggarwal, Ricardo F. Allegri, Sarah B. Berman, Thomas Bird, Sandra E. Black, William S. Brooks, Jasmeer P. Chhatwal, Gregory S. Day, Martin R. Farlow, Nick C. Fox, Serge Gauthier, Lawrence S. Honig, Ging-Yuek Hsiung, Mathias Jucker, Johannes Levin, Mario Masellis, Colin Masters, Patricio Chrem Mendez, John M. Ringman, B. Joy Snider, Stephen Salloway, Peter R. Schofield, Hiroyuki Shimada, Kazushi Suzuki, Christopher H. van Dyck, Gregory Klein, David B. Clifford, Carlos Cruchaga, Jason Hassenstab, Yan Li, Eric McDade, Susan Mills, John C. Morris, Richard J. Perrin, Charlene Supnet-Bell, Guoqiao Wang, Chengjie Xiong, Randall J. Bateman, Tammie L. S. Benzinger, for the DIAN-TU Study Team","doi":"10.1002/alz.70347","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Monoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD).</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>In the DIAN-TU-001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [<sup>11</sup>C]-Pittsburgh compound-B (PiB) positron emission tomography (PET), [<sup>18</sup>F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were associated with baseline PiB-PET uptake, and the largest effects occurred in medial regions.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB-PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Gantenerumab unevenly decreased Aβ burden as measured by PiB-PET across brain regions.</li>\n \n <li>The strongest decrease in PiB-PET uptake was in basal ganglia and medial frontal structures.</li>\n \n <li>Variable drug effect on Aβ was partly due to the amount of burden present before treatment.</li>\n \n <li>There was no regional effect on FDG-PET metabolism or MRI volumetrics after 4 years.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 7","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70347","citationCount":"0","resultStr":"{\"title\":\"Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial\",\"authors\":\"Austin McCullough, Charles D. Chen, Brian A. Gordon, Nelly Joseph-Mathurin, Clifford R. Jack Jr, Robert Koeppe, Russ Hornbeck, Deborah Koudelis, Nicole S. McKay, Diana A. Hobbs, Shaney Flores, Sarah J. Keefe, Neelum T. Aggarwal, Ricardo F. Allegri, Sarah B. Berman, Thomas Bird, Sandra E. Black, William S. Brooks, Jasmeer P. Chhatwal, Gregory S. Day, Martin R. Farlow, Nick C. Fox, Serge Gauthier, Lawrence S. Honig, Ging-Yuek Hsiung, Mathias Jucker, Johannes Levin, Mario Masellis, Colin Masters, Patricio Chrem Mendez, John M. Ringman, B. Joy Snider, Stephen Salloway, Peter R. Schofield, Hiroyuki Shimada, Kazushi Suzuki, Christopher H. van Dyck, Gregory Klein, David B. Clifford, Carlos Cruchaga, Jason Hassenstab, Yan Li, Eric McDade, Susan Mills, John C. Morris, Richard J. Perrin, Charlene Supnet-Bell, Guoqiao Wang, Chengjie Xiong, Randall J. Bateman, Tammie L. S. Benzinger, for the DIAN-TU Study Team\",\"doi\":\"10.1002/alz.70347\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>Monoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD).</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>In the DIAN-TU-001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [<sup>11</sup>C]-Pittsburgh compound-B (PiB) positron emission tomography (PET), [<sup>18</sup>F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI).</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were associated with baseline PiB-PET uptake, and the largest effects occurred in medial regions.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB-PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Gantenerumab unevenly decreased Aβ burden as measured by PiB-PET across brain regions.</li>\\n \\n <li>The strongest decrease in PiB-PET uptake was in basal ganglia and medial frontal structures.</li>\\n \\n <li>Variable drug effect on Aβ was partly due to the amount of burden present before treatment.</li>\\n \\n <li>There was no regional effect on FDG-PET metabolism or MRI volumetrics after 4 years.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 7\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70347\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.70347\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70347","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial
INTRODUCTION
Monoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD).
METHODS
In the DIAN-TU-001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [11C]-Pittsburgh compound-B (PiB) positron emission tomography (PET), [18F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI).
RESULTS
Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were associated with baseline PiB-PET uptake, and the largest effects occurred in medial regions.
DISCUSSION
Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB-PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design.
Highlights
Gantenerumab unevenly decreased Aβ burden as measured by PiB-PET across brain regions.
The strongest decrease in PiB-PET uptake was in basal ganglia and medial frontal structures.
Variable drug effect on Aβ was partly due to the amount of burden present before treatment.
There was no regional effect on FDG-PET metabolism or MRI volumetrics after 4 years.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
